SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damage and constitutes an antiviral target
Z. Gao, B. Xia, X. Shen, Y. He, X. Pan, Y. Wang, F. Yang, S. Fang, Y. Wu, X. Zuo, Z. Xie, X. Jiang, H. Chi, Q. Meng, H. Zhou, Y. Zhou, X. Cheng, T. Cheng, X. Xin, H. Jiang, G. Xiao, Q. Zhao, L.-K. Zhang, J. Shen, J. Li
Abstract
Cytokine storm and multi-organ failure are the main causes of SARS-CoV-2-related death. However, the origin of the virus excessively damaging abilities remains unknown. Here we show that the SARS-CoV-2 envelope (2-E) protein alone is sufficient to cause acute respiratory distress syndrome (ARDS)-like damage in vitro and in vivo. Overexpression of 2-E protein induced rapid pyroptosis-like cell death in various susceptible cells and robust secretion of cytokines and chemokines in macrophages. Intravenous administration of purified 2-E protein into mice caused ARDS-like pathological damage in lung and spleen. Overexpressed 2-E protein formed cation channels in host cell membranes, eventually leading to membrane rupture. Newly identified channel inhibitors exhibited potent anti-SARS-CoV-2 activity and excellent protective effects against the 2-E-induced damage both in vitro and in vivo. Importantly, their channel inhibition, cell protection and antiviral activities were positively correlated with each other, supporting 2-E is a promising drug target against SARS-CoV-2.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Functional pangenome analysis suggests inhibition of the protein E as a readily available therapy for COVID-2019.
Intikhab S. Alam, Allan Anthony Kamau, … Carlos Manuel Duarte·Frontiers in Cellular and Infection MicrobiologyPeer-reviewed·Jul 27, 2020
- Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of k18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2
Gary D. Ewart, Michael D. Bobardt, … Philippe A. Gallay·PLoS PathogensPeer-reviewed·Aug 7, 2023
- SARS-CoV-2 envelope-protein corruption of homeostatic signaling mechanisms in mammalian cells
T. Schulze, A. Hartel, … O. Rauh·bioRxiv·Jun 16, 2021
- SARS-CoV-2 infection alkalinizes the ERGIC and lysosomes through the viroporin activity of the viral envelope protein
W.-A. Want, A. Carreras Sureda, N. Demaurex·bioRxiv·Oct 4, 2022
- Recombinant ACE2 Expression is Required for SARS-CoV-2 to Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses
J. Nascimento Conde, W. R. Schutt, … E. R. Mackow·bioRxiv·Nov 10, 2020
- Molecular mechanism of SARS-Cov-2 components caused ARDS in murine model